NEPHROPLUS vs SUDEEPPHRM: Stock Comparison
Sudeep Pharma Ltd is the larger company by market capitalisation. Nephrocare Health Services Ltd shows lower leverage, while Sudeep Pharma Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NEPHROPLUS leads 2; SUDEEPPHRM leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹697.35 | ₹1,127.2 |
| Day Change | 1.47% | -0.35% |
| Volume | 1.46 L | 1.5 L |
| 52-Week High | ₹769.75 | ₹1,180 |
| 52-Week Low | ₹446 | ₹524.05 |
| Distance from 52W High | -9.41% | -4.47% |
Valuation
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹6,991 Cr | ₹12,743 Cr |
| P/E Ratio | 89.97x | 69.8x |
| P/B Ratio | 6.19x | 14.45x |
| EPS | ₹7.66 | ₹16.8 |
| Book Value | ₹111 | ₹78.2 |
| Dividend Yield | 0% | 0.14% |
Growth
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 21.2% | 26.7% |
| Qtr Profit Growth | 22.1% | 31.6% |
Profitability & Leverage
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| ROE | 9.06% | 25.2% |
| ROCE | 15.5% | 28.2% |
| Net Margin | 7.69% | 27.14% |
| Operating Margin | 22.4% | 34.5% |
| Debt to Equity | 0.07x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 21.07% | 76.15% |
| FII Holding | 8.78%▼ 1.16 pp | 1.81%▲ 0.26 pp |
| DII Holding | 9.05%▲ 0.4 pp | 15.65%▼ 2.46 pp |
| Public Holding | 18.32%▲ 0.76 pp | 6.39%▲ 2.21 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Nephrocare Health Services Ltd and Sudeep Pharma Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.